biotech.today
Scientific intelligence for drug discovery teams
Strategy, R&D, and investment teams use biotech.today to get trusted benchmarks, real-time signals, and expert-vetted analysis to navigate AI-driven drug discovery with clarity.
Explore the platformWhat we deliver
Intelligence that drives decisions
Actionable benchmarks & data —
Analyst-reviewed benchmarks across 60+ AI tools, comparing accuracy, speed, and real-world adoption across drug discovery workflows.
Expert research & deep dives —
Market maps, modality overviews, tool comparisons, and science gap analysis to spot opportunities before the field catches up.
AI-powered signals —
Real-time tracking of tool releases, clinical readouts, deals, and KOL commentary so you stay ahead.
Practitioner network —
Built by drug discovery practitioners, not journalists. Every benchmark, comparison, and analysis grounded in real R&D experience.
Our audience
Who we serve
“Finally, a platform that tells me which tools actually work in production — not just on benchmarks.”
Compare AI models head-to-head, track new tool releases in real time, and benchmark accuracy against your own workflows. Save weeks of evaluation time.
Intelligence Stack
What We Cover
Deep coverage across six core areas of AI-driven drug discovery — tools tracked, workflows mapped, signals monitored.
Structure Prediction
Tools Tracked
- AlphaFold 2 & 3
- Boltz-1 & 2
- Chai-1
- ESMFold
- OpenFold
Key Workflows
- Predict 3D protein structures from sequence
- Model protein-ligand complex geometries
- Generate starting poses for virtual screening
- Validate homology models against experimental data
Data
By the Numbers
See all insightsTool category distribution
91 tools tracked across 11 categories
Deal flow by quarter
Clinical pipeline by modality
Research
Explore the latest
View allThe State of AI in Drug Discovery: 2026 Landscape
More than 200 AI-designed drugs are now in clinical development. Phase I success rates for AI-discovered compounds are running between 80–90%, roughly double the historical average. The hype cycle is over.
Protein Structure Prediction: From AlphaFold to Boltz-2
Boltz-2 can co-fold a protein–ligand pair and output both the 3D complex and a binding affinity estimate in about 20 seconds on a single GPU. That capability didn't exist 18 months ago.
PROTAC Renaissance: How AI is Reviving Protein Degradation
Arvinas and Pfizer's vepdegestrant (ARV-471) has its FDA approval expected by June 2026 — making it potentially the first PROTAC ever approved. Meanwhile, AI is solving the design challenges that held the field back for a decade.
The Weekly Briefing
Join practitioners getting the signal, not the noise. One email per week covering tool launches, clinical readouts, and science gaps in AI drug discovery.
Join us
Built for practitioners
biotech.today is built by scientists running AI tools on real drug targets — not by journalists reading abstracts. See why teams trust our intelligence.
Explore the platform